AbbVie Inc. stock (US00287Y1091): Q1 2026 sales surge on immunology and aesthetics growth

AbbVie Inc. reports double?digit revenue growth in Q1 2026, driven by immunology brands Skyrizi and Rinvoq and aesthetics products, while heavy non?cash charges weigh on net earnings.

AbbVie Inc. has reported first?quarter 2026 results that highlight strong double?digit revenue growth, underpinned by its immunology and aesthetics portfolios, even as elevated non?cash charges and deal?related expenses pressure net earnings and EPS. Net revenues reached $15.0 billion, up 12.4% year over year (about 10.3% in constant currency), according to the company’s 10?Q filing and a summary on Stock Titan as of May 8, 2026.

Immunology drugs Skyrizi and Rinvoq were key growth engines, with Skyrizi generating $4.48 billion in worldwide net revenues in the quarter, up 30.9% year over year, and Rinvoq also posting around 20% growth. Neuroscience brands such as Vraylar, Botox Therapeutic, Ubrelvy and Qulipta, as well as aesthetics products including Botox Cosmetic, contributed solid gains, while legacy products Humira and Imbruvica continued to face pressure from biosimilars and competition. Operating earnings rose to $4.0 billion, but net earnings attributable to AbbVie fell to $695 million and diluted EPS to $0.39, largely due to a $2.39 billion non?cash increase in contingent consideration liabilities and $744 million of acquired in?process R&D and milestone expenses, including a $650 million upfront payment to RemeGen, as detailed in the 10?Q and Stock Titan coverage as of May 8, 2026.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AbbVie Inc.
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: North Chicago, Illinois, United States
• Core markets: United States, Europe, Japan and other global markets
• Key revenue drivers: Immunology (Skyrizi, Rinvoq), neuroscience and aesthetics (Botox), oncology and other specialty therapies
• Home exchange/listing venue: New York Stock Exchange (NYSE: ABBV)
• Trading currency: U.S. dollar (USD)

AbbVie Inc.: core business model

AbbVie Inc. operates as a global biopharmaceutical company focused on developing and commercializing innovative medicines across several therapeutic areas, including immunology, oncology, neuroscience, eye care and aesthetics. The company’s business model centers on a diversified portfolio of branded specialty products, supported by a large late?stage pipeline and ongoing strategic acquisitions and partnerships. AbbVie’s strategy emphasizes high?margin, patent?protected therapies in areas with significant unmet medical need, which allows it to command premium pricing while reinvesting in R&D and external innovation.

Immunology remains the cornerstone of AbbVie’s franchise, anchored by Skyrizi and Rinvoq, which target autoimmune conditions such as psoriasis, psoriatic arthritis and inflammatory bowel disease. Neuroscience and aesthetics, led by Botox in both therapeutic and cosmetic indications, provide additional growth levers and geographic diversification. The company also maintains a presence in oncology and other specialty areas, although these segments face increasing competition and biosimilar erosion, particularly around legacy products like Humira and Imbruvica.

Main revenue and product drivers for AbbVie Inc.

Immunology is the primary revenue driver for AbbVie, with Skyrizi and Rinvoq delivering double?digit growth in Q1 2026. Skyrizi’s worldwide net revenues of $4.48 billion in the quarter, up 30.9% year over year, reflect expanding indications and strong uptake in both the United States and international markets. Rinvoq also grew around 20%, benefiting from label expansions and growing physician adoption in inflammatory diseases. These brands are expected to offset declining sales of Humira, which continues to face biosimilar competition in key markets.

Neuroscience and aesthetics are the next?largest growth pillars. Neuroscience brands such as Vraylar (for schizophrenia and bipolar disorder), Botox Therapeutic, Ubrelvy and Qulipta (for migraine) posted solid growth, supported by broadening indications and continued demand. Aesthetics, led by Botox Cosmetic, remains a high?margin, cash?generating business with strong consumer demand and pricing power. Together, these segments help AbbVie maintain overall revenue momentum even as older oncology products like Imbruvica see slower growth or decline.

Why AbbVie Inc. matters for US investors

For US investors, AbbVie offers exposure to a large?cap, dividend?paying pharmaceutical stock with a diversified global portfolio and a strong presence in the US healthcare market. The company’s immunology and aesthetics franchises are particularly relevant in the United States, where specialty drug spending and aesthetic procedures are growing. AbbVie’s listing on the NYSE and its inclusion in major US equity indices make it a core holding for many income?oriented and growth?oriented portfolios.

AbbVie’s recent Q1 2026 performance underscores its ability to generate robust top?line growth despite patent expiries and biosimilar pressure, which is a key consideration for investors seeking resilient cash flows in the healthcare sector. At the same time, the company’s heavy R&D and deal?related spending, along with elevated non?cash charges, highlight the importance of monitoring earnings quality and capital allocation decisions.

Conclusion

AbbVie Inc. delivered double?digit revenue growth in Q1 2026, driven by strong performance in immunology, neuroscience and aesthetics, even as non?cash charges and deal?related expenses weighed on net earnings and EPS. The company’s diversified portfolio and late?stage pipeline position it to continue growing sales, but investors should remain mindful of earnings volatility, patent?related risks and the impact of biosimilar competition on legacy products. For US investors, AbbVie offers a combination of growth, cash flow and dividend income, but the stock’s valuation and capital?allocation choices will be critical factors in its long?term performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.